Brief: Nanobiotix: FDA Protocol Acceptance For New Randomized Phase 2 Study Evaluating NBTXR3

Nanobiotix SA

15/05/2024 06:56

May 15 (Reuters) - Nanobiotix SA  NANOB.PA :
    * ANNOUNCED ON TUESDAY US FDA PROTOCOL ACCEPTANCE FOR NEW
RANDOMIZED PHASE 2 STUDY EVALUATING NBTXR3 FOR PATIENTS WITH
STAGE THREE LUNG CANCER
    * AN IND TO SUPPORT THIS TRIAL WAS SUBMITTED BY GLOBAL TRIAL
SPONSOR, JOHNSON & JOHNSON ENTERPRISE INNOVATION, A JOHNSON &
JOHNSON  JNJ.N  COMPANY

Source text for Eikon:  ID:nGNE3SX1C0 
Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))